May 26, 2016
Wellesley, Mass., May 26, 2016 – Since its commercial introduction in 2005, next-generation sequencing (NGS) has matured into an essential life science tool for conducting genetic studies in a range of research and development applications. BCC Research reveals in its new report that the industry sits on the beginnings of a second growth phase, one powered by a range of new applications in the clinical diagnostics and applied fields
Since the Human Genome Project (HGP) was completed in 2003, the life sciences industry has undergone a major transformation. DNA sequencing technologies have led the way in this transformation. Sequencing markets center around three generations of platforms: Sanger sequencing, next-generation sequencing (NGS), and third-generation sequencing (3GS).
The worldwide market for sequencing products was $5.9 billion in 2015 and is forecast to grow at a five-year compound annual growth rate (CAGR) of 18.7% to reach nearly $13.8 billion by the year 2020. The market can be segmented into pre- and post-sequencing products (i.e., sample preparation reagents and kits, and informatics); sequencing instruments and consumables (i.e., flow cells and consumables used in the sequencing reaction itself); and sequencing services. Sequencing services, the largest market segment, also is the fastest-growing one with an anticipated five-year CAGR of 26%.
For clinical, the main applications driving growth are cancer and reproductive health. In cancer, there is a growing need for genomic profiling tests that can be used as the basis for treatment decisions. This is part of a general trend for characterizing cancer on a genomics, rather than anatomic, basis. Also, the maturation of large-scale government research initiatives like the Cancer Genome Atlas should spur growth in this market. These projects help to uncover the underlying genomic basis for cancer, creating a need for sequencing diagnostics to help evaluate, treat and monitor cancer cases.
Non-invasive prenatal diagnostics (NIPT), for high-risk women, should drive growth in the reproductive health application. In-vitro fertilization, carrier screening, newborn screening, and NIPT for average-risk women are anticipated as key drivers, as well.
“Next-generation sequencing, commercially introduced in 2005, is still experiencing high growth in new market applications such as clinical and consumer sequencing,” says BCC Research analyst John Bergin. “Emerging sequencing systems, such as single molecular or nanopore sequencing, are still in an early market stage, with platforms only recently introduced. These new sequencing technologies promise to fill new market niches that are presently underserved by the main sequencing technologies.”
DNA Sequencing: Emerging Technologies and Applications (BIO045F) analyzes major sequencing trends as well as the key companies and industry sectors. The in-depth analysis provides insights into sequencing’s transition into clinical and applied markets, giving a solid roadmap to participants and new entrants into this dynamic industry. Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020 also are provided.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
DNA Sequencing: Emerging Technologies and Applications( BIO045F )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.